Injection-site sarcomas or mammary tumors in cats
The purpose of the study is to evaluate a new imaging method to detect cancer cells left behind following removal of injection-site sarcomas (FISS) and mammary tumors in cats undergoing surgery. This technology has been used successfully in human breast cancer surgery, providing microscopic assessment of surgical margins within minutes. Identifying a rapid and thorough imaging method to detect any remaining cancer cells during surgery for sarcomas especially FISS and mammary tumors will support targeted treatment management decisions and improve outcomes for cats and dogs with cancer.
What qualifies my pet for enrollment in this in this trial?
To participate in this clinical trial your cat must:
- Have cytology or histopathology confirmation of soft tissue sarcoma or injection site sarcoma or mammary tumor
- undergo surgical excision of sarcoma or mammary tumor at OSU
What does enrolling my pet in this clinical trial involve?
Cats will undergo surgery to remove their tumor, following removal the tumor will be scanned with polarization sensitive optical coherence tomography to assess the surgical margins for residual cancer cells. The specimen will then undergo thorough histopathological assessment.
Client Compensation
Pet owners are financially responsible for all costs associated with evaluation and surgery. Each pet owner receiving surgery at OSU will receive $70 credit to their account to cover the costs of the histopathology evaluation.
PRE-SCREENING QUESTIONNAIRE
If you believe your pet may be eligible to enter this study, please fill out a pre-screening questionnaire.